Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 1-2
Submit an article Journal homepage
123
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma

Ahmad Z Al Meslamania College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates;b AAU Health and Biomedical Research Quality of Care Center, Al Ain University, Abu Dhabi, United Arab EmiratesCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8370-9562View further author information
ORCID Icon
Pages 25-29 | Received 02 Nov 2023, Accepted 03 Jan 2024, Published online: 05 Jan 2024

References

  • The global asthma network, “the global asthma report 2022”. 2022 [cited 2023 Sep 10]. [Online]. Available from: http://globalasthmareport.org/
  • World Health Organisation. WHO. Asthma. 2020 [cited 2023 Dec. 9]. Available from: https://www.who.int/news-room/facts-in-pictures/detail/asthma
  • Patel VH, Thannir S, Dhanani M, et al. Current limitations and recent advances in the management of asthma. Dis Mon. 2023 Jul;69(7):101483.
  • Bousquet J, Chiron R, Humbert M. Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther. 2008 Dec;8(12):1921–1928. doi: 10.1517/14712590802496928
  • Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018 Jul;18(7):747–754. doi: 10.1080/14712598.2018.1492540
  • Salter B, Lacy P, Mukherjee M. Biologics in asthma: a molecular perspective to precision medicine. Front Pharmacol. 2021;12:793409. doi: 10.3389/fphar.2021.793409
  • Scioscia G, Nolasco S, Campisi R, et al. Switching biological therapies in severe asthma. Int J Mol Sci. 2023 May;24(11):9563.
  • Parulekar AD, Diamant Z, Hanania NA. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med. 2016 Jan;22(1):59–68. doi: 10.1097/MCP.0000000000000231
  • Al Ghobain MO, Alsubaie AS, Aljumah WA, et al. The correlation between fractional exhaled nitric oxide (FeNO), blood eosinophil Count, immunoglobulin E levels, and spirometric values in patients with asthma. Cureus. 2023 Feb;15(2):e35289.
  • Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020 Feb;75(2):311–325. doi: 10.1111/all.13985
  • Iftikhar IH, Schimmel M, Bender W, et al. Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung. 2018 Oct;196(5):517–530. doi: 10.1007/s00408-018-0151-5
  • Gon Y, Maruoka S, Mizumura K. Omalizumab and IgE in the control of severe allergic asthma. Front Pharmacol. 2022;13:839011. doi: 10.3389/fphar.2022.839011
  • López-Viña A, Díaz Campos RM, Trisan Alonso A, et al. Uncontrolled severe T2 asthma: which biological to choose? A biomarker-based approach. Front Allergy. 2022;3:1007593. doi: 10.3389/falgy.2022.1007593
  • Runnstrom M, Pitner H, Xu J, et al. Utilizing predictive inflammatory markers for guiding the use of biologicals in severe asthma. J Inflamm Res. 2022;15:241–249. doi: 10.2147/JIR.S269297
  • Nair P, Prabhavalkar KS. Neutrophilic asthma and potentially related target therapies. Curr Drug Targets. 2020;21(4):374–388. doi: 10.2174/1389450120666191011162526
  • Mukherjee M, Nair P. Autoimmune Responses in Severe Asthma. Allergy Asthma Immunol Res. 2018 Sep;10(5):428–447. doi: 10.4168/aair.2018.10.5.428
  • Campisi R, Nolasco S, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with Co-presence of Bronchiectasis: a real-world multicentre observational study. J Clin Med. 2023;12(12):3953. doi: 10.3390/jcm12123953
  • Portacci A, Dragonieri S, Carpagnano GE. Super-responders to biologic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype? J Allergy Clin Immunol Pract. 2023 May;11(5):1417–1420. doi: 10.1016/j.jaip.2023.01.021
  • Gautam Y, Johansson E, Mersha TB. Multi-omics profiling approach to asthma: an evolving paradigm. J Pers Med. 2022 Jan;12(1). doi: 10.3390/jpm12010066
  • Papaioannou AI, Fouka E, Bartziokas K, et al. Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission. Expert Rev Respir Med. 2023;17(6):481–493. doi: 10.1080/17476348.2023.2226392

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.